The anti-psychotic drug Pimozide is a Novel chemotherapeutic for Breast Cancer

El-Habib, Dakir, Pickard, Adam, Sirvastava, Kirtiman, Mc Crudden, Cian, Gross, Stephane R, Llyod, Stephan, Zhang, Shu-Dong, Margariti, Adrianna, Morgan, Richard, Rudland, Philip S. and El-Tanani, Mohamed (2018). The anti-psychotic drug Pimozide is a Novel chemotherapeutic for Breast Cancer. Oncotarget, 9 (79), pp. 34889-34910.

Abstract

Pimozide, an antipsychotic drug of the diphenylbutylpiperidine class, has been shown to suppress cell growth of breast cancer cells in vitro. In this study we further explore the inhibitory effects of this molecule in cancer cells. We found that Pimozide inhibited cell proliferation in a dose- and time-dependent manner in MDA-MB-231 breast cancer cells and A549 lung cancer cells. Furthermore, we found that Pimozide also promoted apoptosis as demonstrated by cell cycle arrest and induction of double-strand DNA breaks but did not result in any effect in the non-transformed MCF10A breast cell line. In order to shed new lights into the molecular pathways affected by Pimozide, we show that Pimozide downregulated RAN GTPase and AKT at both protein and mRNA levels and inhibited the AKT signaling pathway in MDA-MB-231 breast cancer cells. Pimozide also inhibited the epithelial mesenchymal transition and cell migration and downregulated the expression of MMPs. Administration of Pimozide showed a potent in vivo antitumor activity in MDA-MB-231 xenograft animal model and reduced the number of lung metastases by blocking vascular endothelial growth factor receptor 2. Furthermore, Pimozide inhibited myofibroblast formation as evaluated by the reduction in α-smooth muscle actin containing cells. Thus, Pimozide might inhibit tumor development by suppressing angiogenesis and by paracrine stimulation provided by host reactive stromal cells. These results demonstrate a novel in vitro and in vivo antitumor activity of Pimozide against breast and lung cancer cells and provide the proof of concept for a putative Pimozide as a novel approach for cancer therapy.

Publication DOI: https://doi.org/10.18632/oncotarget.26175
Divisions: Life & Health Sciences
Life & Health Sciences > Biosciences
Additional Information: © Dakir et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Uncontrolled Keywords: Pimozide, Breast cancer, Apoptosis, Xenograft, Ran, VEGFR2
Full Text Link:
Related URLs: http://www.onco ... ubmed-linkout=1 (Publisher URL)
Published Date: 2018-10-09
Authors: El-Habib, Dakir
Pickard, Adam
Sirvastava, Kirtiman
Mc Crudden, Cian
Gross, Stephane R ( 0000-0002-0867-8866)
Llyod, Stephan
Zhang, Shu-Dong
Margariti, Adrianna
Morgan, Richard
Rudland, Philip S.
El-Tanani, Mohamed

Download

[img]

Version: Published Version

License: Creative Commons Attribution

| Preview

[img]

Version: Accepted Version

Access Restriction: Restricted to Repository staff only


Export / Share Citation


Statistics

Additional statistics for this record